Integrated Advisors Network LLC Sells 3,258 Shares of Axon Enterprise, Inc $AXON

Integrated Advisors Network LLC trimmed its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 70.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,338 shares of the biotechnology company’s stock after selling 3,258 shares during the period. Integrated Advisors Network LLC’s holdings in Axon Enterprise were worth $960,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. NEOS Investment Management LLC raised its holdings in Axon Enterprise by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after acquiring an additional 11,482 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after purchasing an additional 376,904 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Axon Enterprise by 3.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after purchasing an additional 5,953 shares in the last quarter. BIT Capital GmbH increased its holdings in shares of Axon Enterprise by 75.6% in the third quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock valued at $2,537,000 after purchasing an additional 1,522 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC lifted its position in Axon Enterprise by 180.7% during the second quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after buying an additional 775 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Down 1.4%

Shares of AXON stock opened at $542.40 on Monday. Axon Enterprise, Inc has a fifty-two week low of $396.41 and a fifty-two week high of $885.91. The company has a 50 day moving average price of $537.92 and a 200 day moving average price of $623.54. The stock has a market capitalization of $43.61 billion, a P/E ratio of 356.84, a price-to-earnings-growth ratio of 12.23 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. During the same period in the previous year, the firm posted $2.08 EPS. Axon Enterprise’s revenue for the quarter was up 38.5% on a year-over-year basis. Equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Insider Activity

In other news, President Joshua Isner sold 20,000 shares of Axon Enterprise stock in a transaction on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the transaction, the president directly owned 249,502 shares of the company’s stock, valued at $137,874,805.20. The trade was a 7.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeri Williams sold 100 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $550.63, for a total transaction of $55,063.00. Following the completion of the sale, the director directly owned 1,316 shares of the company’s stock, valued at $724,629.08. The trade was a 7.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 58,040 shares of company stock worth $32,251,738 over the last three months. Company insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on AXON shares. Needham & Company LLC cut their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research note on Wednesday. Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Craig Hallum restated a “buy” rating and set a $820.00 price target on shares of Axon Enterprise in a report on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.